Vir Biotechnology, Inc. Free Cash Flow 2017–2025
Vir Biotechnology, Inc. reported $-396.61M of free cash flow for fiscal 2025. That was 12.6% higher than fiscal 2024. Compared with fiscal 2020, the change was -100.8%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $-396.61M | +12.6% |
| FY 2024 | $-453.65M | +43.3% |
| FY 2023 | $-800.36M | -150.2% |
| FY 2022 | $1.60B | +2398.4% |
| FY 2021 | $-69.41M | +64.9% |
| FY 2020 | $-197.49M | -42.5% |
| FY 2019 | $-138.57M | -35.5% |
| FY 2018 | $-102.29M | -48.0% |
| FY 2017 | $-69.12M | — |
Source: Vir Biotechnology, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open VIR 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Vir Biotechnology, Inc. reported $-396.61M of free cash flow for fiscal 2025. That was 12.6% higher than fiscal 2024. Compared with fiscal 2020, the change was -100.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Vir Biotechnology, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeVir Biotechnology, Inc. — frequently asked questions
What is Vir Biotechnology, Inc.'s free cash flow?
Vir Biotechnology, Inc. (VIR) reported free cash flow of $-396.61M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Vir Biotechnology, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.